Member Info for SteveV

SP looking a bit oversold right now. Don't know why? This coming quarter will probably be JKX most profitable to date.
Looking forward to an upward rebound soon.!!

Hmmm. a ten minute PCR test, now that would be something.

PCR tests carried out in the UK yesterday, 14th October 2021...... 429,658
PCR tests carried out same time last year, 14th October 2020...... 295,690

That is just the UK, .......and we got winter to come. PCR testing is increasing NOT decreasing.
https://coronavirus.data.gov.uk/details/testing

Demand for gas is high and stocks are low.
Russia pumping more gas will reduce prices a LITTLE bit but still massive revenues for gas producers for the foreseable, I would have thought. JKX will do very nicely over this autumn/winter.

Very difficult for a private investor to influence the BODs' strategy.

Probably best to support what they want to do. OR, if you don't agree with it, sell your shares and move on.

"..i cant quite get my head around it tbh how two markets can maintain a similar price point if we are buying strong here but they are selling strong in France ?..."

Yes, I have posed this question before but no one seemed to have an answer.

You might think that to balance the books shares would have to be transferred from one market to the other. BUT that doesn't seem to happen because we seem to maintain a 66% -33% split between the French an English share of the shares in issue.
So what happens....anyone know?

Winterplex should do well this year, especially as the Covid symtptoms are now less distinguishable from flu etc.

You would think GM would want to go out on a high but it's looking more like under a cloud.
DHSC dispute a shambles. How much of his bonus was based on the sp as a consequence of the original contract that looked so amazing.
And now, BOD can't even get enough votes to get the AGM sorted.

Can he redeem the situation in the next 19 days? Surely NCYT have something up their sleeve. Just let us know....PLEASE

Let's wait and see what the new CEO's bonus package is, then we will get an idea which way the sp will be headed !!
If it's heavily linked to sp performance you can bet that will make a remarkable recovery.

Lol, yes. I've always wanted one.

"...building our product and instrument platforms..."

Wonder if that means they are working on a new machine to compliment the Q16/32's.

I'd like to see a Q1. A small hand held easy to use single sample testing machine. I could imagine every ward in every hospital might want one. Test every new patient before they come into a ward. A 15 min saliva test would be amazing. Check for Covid, flu, RSV...or anything they want really. Near patient testing is supposedly where we are headed.

NOW..... would be a good time to end the dispute(s), secure some finance, extend the PSC, and start drilling for GAS !!!.

Eventually ...... the market will wake up to the reality, regardless of LFT. PCR, as to which companies are generating huge revenues/profit.
Shocking how NCYT is compared to all the loss making companies that have not made a penny from Covid tests as yet.

No Problem NCYT selling all the LFT's they can produce then if lack of supply is the issue.

Great, we will be knocking out LFT's and PCR's all Autumn and Winter.

Avacta down almost 6%. NCYT up 8%....Yep PCR is dead. !!!

Hey Poidster, are you of the opinion that ALL Promate ever delivered including that which in dispute has been used?

DHSC is withholding payment for a big chunk of Promate from earlier in the year in lieu of wanting a refund from un-used original tests from last year ?

Just waiting for news from our recently expanded sales force in the US.

Nice juicy contract would do wonders.

Yes, EKF currently trading around 5 x revenue.
NCYT at 100m revenue should be around £7.

The PCR travel tests have very nicely filled a summer gap for NCYT to keep the revenue flowing. The holiday season is largely over.
We have Autumn/winter to come, busiest time for NCYT.
Who knows what next year will bring.
Being a salesman I bet our new CEO's RNS's are a lot more positive than previous looking forward.

£7 per share for NCYT should be no problem at all. High margin diagnostics healthcare provider with revenue of £100M per
year. Much more if a takeover bid transpires.

The market is just unsure how revenues will pan out 2022,2023.etc.